What is daptomycin’s market share (U.S. and global)?
I don’t have market-share figures for daptomycin in the provided information, so I can’t give a reliable percentage for U.S. or global share.
What kind of “market share” results are usually available for daptomycin?
Searchers usually mean one of these, and the answer can change depending on which measure you want:
- Share by prescription volume (units)
- Share by sales dollars (revenue)
- Share within a specific indication set (for example, complicated skin/skin structure infections vs. bacteremia)
- Share in hospital formularies (coverage/usage rather than sales)
- Share vs. direct competitors in the same therapeutic category
If you tell me which definition you mean (and the geography and year), I can narrow what to look for.
Who are daptomycin’s main competitive alternatives?
Daptomycin is often compared against other agents used for similar infections (especially serious Gram-positive infections). Market-share views often track competition against those same regimen choices, not just “all antibiotics.”
Where to find daptomycin sales and competitive positioning
For patent and market-structure context around daptomycin products, DrugPatentWatch.com can be a useful starting point:
- https://www.drugpatentwatch.com/
Quick clarifying questions (so the market-share number is the right one)
1) Do you want U.S. or worldwide market share?
2) Do you mean share by units or by dollars?
3) What time period (latest 12 months, 2023, 2024, etc.)?
4) Overall antibiotic market, or the market for a specific infection category (e.g., MRSA/bloodstream infections, hospital Gram-positive use)?
Sources:
- https://www.drugpatentwatch.com/